Literature DB >> 21244653

Primary malignant mixed Müllerian tumor arising from the mesorectum with a synchronous ovarian cancer: a case report and review of the literature.

Chuang-Chi Huang1, Cheng-Jen Ma, Wan-Ting Huang, Te-Fu Chan, Jaw-Yuan Wang.   

Abstract

INTRODUCTION: Extragenital malignant mixed Müllerian tumor is an extremely rare presentation of malignant mixed Müllerian tumor, especially when combined with a synchronous ovarian cancer. CASE
PRESENTATION: We report the clinical course and pathologic findings of a case of mesorectal malignant mixed Müllerian tumor with synchronous ovarian cancer, in a 50-year-old, gravida 0, para 0, Han Chinese woman with regular menstruation. This is the sixteenth case in the English literature of extragenital malignant mixed Müllerian tumor combined with synchronous or metachronous malignancy reported.
CONCLUSION: Although extragenital malignant mixed Müllerian tumor is very rare and has a poor prognososis, a longer survival time might be achieved with treatment by cytoreductive surgery, radiotherapy and chemotherapy.

Entities:  

Year:  2011        PMID: 21244653      PMCID: PMC3224474          DOI: 10.1186/1752-1947-5-15

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  24 in total

1.  Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report.

Authors:  M SWERDLOW
Journal:  Am J Obstet Gynecol       Date:  1959-01       Impact factor: 8.661

2.  Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases.

Authors:  P G Rose; M Rodriguez; F W Abdul-Karim
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

3.  Synchronous colonic adenocarcinoma and extragenital malignant mixed mesodermal tumour.

Authors:  J N el-Jabbour; C W Helm; K M McLaren; G E Smart; J Aitken
Journal:  Scott Med J       Date:  1989-12       Impact factor: 0.729

Review 4.  Extragenital primary mixed malignant mesodermal tumor.

Authors:  O G Solis; H X Bui; J H Malfetano; J S Ross
Journal:  Gynecol Oncol       Date:  1991-11       Impact factor: 5.482

5.  Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine.

Authors:  S R Simon; S E Wang; M Uhl; S Shackney
Journal:  Gynecol Oncol       Date:  1991-05       Impact factor: 5.482

6.  Extragenital mixed heterologous tumor of müllerian type arising in retroperitoneum.

Authors:  C W Herman; A N Tessler
Journal:  Urology       Date:  1983-07       Impact factor: 2.649

7.  Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it?

Authors:  M Ozguroglu; A Bilici; S Ilvan; H Turna; B Atalay; N Mandel; I Sahinler
Journal:  Int J Gynecol Cancer       Date:  2007-09-24       Impact factor: 3.437

Review 8.  Extragenital malignant mixed müllerian tumor.

Authors:  K T Chen; R W Wolk
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

9.  Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.

Authors:  Yoshiki Mikami; Sakae Hata; Takako Kiyokawa; Toshiaki Manabe
Journal:  Mod Pathol       Date:  2002-09       Impact factor: 7.842

Review 10.  Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.

Authors:  Douglas A Levine; Peter A Argenta; Cindy J Yee; David S Marshall; Narciso Olvera; Faina Bogomolniy; Jamal A Rahaman; Mark E Robson; Kenneth Offit; Richard R Barakat; Robert A Soslow; Jeff Boyd
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

View more
  2 in total

1.  Primary malignant mixed müllerian mesodermal tumor mimicking a rectosigmoid carcinoma: a case report and review of the literature.

Authors:  Sakshi Kapur; Levin Miles
Journal:  Case Rep Oncol Med       Date:  2014-02-10

2.  Primary retroperitoneal müllerian adenocarcinoma: a case report and literature review.

Authors:  C Spinelli; S Strambi; D Tartaglia; G Di Franco; V Pucci; P Faviana; M Lencioni
Journal:  Case Rep Oncol       Date:  2013-12-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.